Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial.

Richard B Lipton Andrea M HarriottJulia Y MaJonathan H SmithJonathan StokesPranav GandhiKrutika Jariwala-ParikhGabriel S JensenJoel M Trugman David W Dodick

Published in: Neurology (2024)

This study provides Class II evidence that taking ubrogepant 100 mg during a migraine prodrome allows more patients to function normally over the next 24 hours.

Keyphrases

patient reported outcomes
end stage renal disease
phase iii
ejection fraction
phase ii
newly diagnosed
clinical trial
chronic kidney disease
open label
double blind
peritoneal dialysis
study protocol
randomized controlled trial
placebo controlled